Lunit Presents 6 AI Biomarker Research Papers at American Association for Cancer Research Immuno-Oncology Conference

Tumor Microenvironment Analysis
Confirming the Possibility of 'Personalized Cancer Treatment'

Medical AI company Lunit announced on the 4th that it will present six research abstracts focused on the AI biomarker 'Lunit Scope' in poster sessions at the '2023 Society for Immunotherapy of Cancer (SITC 2023)' held in San Diego, USA, from the 1st to the 5th of next month.

Lunit's artificial intelligence (AI) biomarker 'Lunit Scope IO'.
[Photo by Lunit]

Since becoming the first medical AI company to participate in SITC, the world's most prestigious conference in the field of immuno-oncology, in 2021, Lunit has attended the conference annually to present its latest research achievements.

At SITC 2023, Lunit will present research on the spatial analysis of tumor-infiltrating lymphocytes (TILs), immune cells, within the tumor microenvironment (TME) of non-small cell lung cancer (NSCLC) that developed resistance after treatment with the targeted therapy epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).

Additionally, presentations will include ▲ a study analyzing the correlation between triple-negative breast cancer (TNBC) and tumor-infiltrating lymphocytes using AI ▲ research on the correlation between methylation (which affects gene expression and disease occurrence) and immunogenicity in various cancers using AI ▲ a study on the association between tumor fragmentation clusters and the immune environment ▲ AI-based immune phenotype (IP) analysis in triple-negative breast cancer ▲ and results from a phase 1/2a clinical trial of a new anti-PD-1 therapy for advanced solid tumors.

Seobum Seok, CEO of Lunit, said, "The presentation of AI biomarker research results related to immuno-oncology, which has become the mainstream of cancer treatment, at the conference brings us one step closer to the possibility of personalized cancer treatment that Lunit aims for. We will continue to strive to enable Lunit Scope to objectively analyze the tumor microenvironment and be used in a wider variety of cancer types."

Founded in 1984, SITC is the largest global society in the field of immuno-oncology, with more than 4,500 medical and industry experts from 63 countries worldwide as members.

This content was produced with the assistance of AI translation services.